Project Grant R01CA281740
- This $1.39M Project Grant from the National Institute of Mental Health under the Mental Health Research Grants program (CFDA 93.242) supports a hybrid effectiveness/implementation cluster randomized trial examining single session interventions (SSIs) and interpersonal therapy for adolescent depression in Mozambican primary care clinics. The project, awarded to Columbia University's Health Sciences Division on September 1, 2025, with completion targeted for June 30, 2030, will deliver...
- Summary San Diego State University Research Foundation received a $213,381 K23 Mentored Patient-Oriented Research Career Development Award from the National Institute of Mental Health under the Mental Health Research Grants program (CFDA 93.242), effective August 1, 2025 through July 31, 2030. This award funds advanced training and career development for the principal investigator to establish an independent research program addressing mental health service disparities among youth from...
- This $1,073,982 National Cancer Institute project grant will fund research at Washington University in University City, Missouri from January 2023 through December 2027 under the Cancer Cause and Prevention Research program (CFDA 93.393). The research aims to document unmet social needs among 300 patient-caregiver dyads where the patient has breast or gynecologic cancer. It will analyze how social needs affect biopsychosocial outcomes for patients and caregivers, including depressive symptoms,...
- Federal Grant Award Summary The National Cancer Institute (CFDA 93.393 – Cancer Cause and Prevention Research) awarded the University of Virginia a $3.36 million Project Grant on September 24, 2025, to evaluate the efficacy and optimal sequencing of two evidence-based digital interventions designed to address co-occurring insomnia and depression in breast cancer survivors. The research will utilize SHUTi (an automated cognitive-behavioral therapy application for insomnia) and IntelliCare (a...
- Summary The National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), awarded a Cooperative Agreement of $6,964,050 to the University of Colorado-Denver on August 6, 2025, extending through July 31, 2030, to establish and operate the Advancing the Science of Palliative Care Research Across the Lifespan (ASCENT) Consortium. The ASCENT Consortium serves as a national hub that advances innovative, high-quality palliative care research by developing...
- Federal Grant Award Summary The National Cancer Institute awarded MGH Institute of Health Professions, Inc. a Project Grant totaling $696,498 (Award Date: May 1, 2026; Completion Date: April 30, 2031) under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and optimize a multicomponent intervention designed to improve functional recovery and participation in life activities among breast cancer survivors. The research will utilize the Multiphase Optimization Strategy...
- Federal Cooperative Agreement Summary Brigham & Women's Hospital, in partnership with Harvard T.H. Chan School of Public Health and Cambridge Health Alliance, received a $3.38M Cooperative Agreement from the National Institute of Mental Health under the Mental Health Research Grants program (CFDA 93.242) to develop dynamic decision support tools for precision treatment-resistant depression (TRD) care. The award, effective September 1, 2025 through August 31, 2027, addresses the clinical need...
- Federal Grant Award Summary The National Cancer Institute awarded a $1.72 million Project Grant to Massachusetts General Hospital on June 1, 2025 (ultimate completion date April 30, 2030) under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds a randomized controlled trial of TARGET-PC, a five-session palliative care intervention designed to improve end-of-life (EOL) care outcomes for patients with metastatic breast cancer (MBC) and their family caregivers. The...
- Federal Grant Award Summary This $6.2 million Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports a four-year clinical research study beginning September 1, 2025, at Indiana University Indianapolis. The project delivers a randomized controlled trial examining whether Internet Cognitive Behavioral Therapy for Depression (ICBT-D) reduces...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will provide $402,401 to the University of Missouri System to conduct a pilot study on the feasibility and impact of a metacognitive strategy training (MCST) intervention for women with cancer-related cognitive impairment (CRCI) following breast cancer treatment. The study aims to examine the effects of MCST on cognitive performance, frontoparietal neural functioning, and functional...
EVALUATION OF A PROACTIVE IDENTIFICATION AND DIGITAL MENTAL HEALTH INTERVENTION APPROACH TO ADDRESS UNMET PSYCHOSOCIAL NEEDS OF INDIVIDUALS LIVING WITH LIKELY INCURABLE CANCER - ABSTRACT INDIVIDUALS LIVING WITH LIKELY INCURABLE CANCER (ILLIC) ARE A HETEROGENEOUS, GROWING SUBPOPULATION OF CANCER SURVIVORS WHO HAVE UNIQUE SURVIVORSHIP CARE NEEDS. PRINCIPAL AMONG THESE IS THE NEED FOR PSYCHOSOCIAL TREATMENT. TREATMENT OF DEPRESSION IS PARTICULARLY CRITICAL AS UP TO HALF OF ILLIC REPORT DEPRESSIVE SYMPTOMS, WITH NEGATIVE SEQUALAE INCLUDING LOWER QUALITY OF LIFE, DESIRE FOR HASTENED DEATH, AND SUICIDALITY. NUMEROUS TRIALS AND META-ANALYSES HAVE DOCUMENTED THAT EVIDENCE-BASED PSYCHOSOCIAL TREATMENT IMPROVES DEPRESSION OUTCOMES FOR ILLIC. HOWEVER, MULTILEVEL BARRIERS LIMIT ACCESS. THUS, ILLIC NEED FEASIBLE, ACCESSIBLE DEPRESSION TREATMENT OPTIONS. BRIEF DEPRESSION SCREENERS ARE NOW ROUTINELY ADMINISTERED IN ONCOLOGY SETTINGS. THESE DATA CAN BE USED TO PROACTIVELY IDENTIFY SURVIVORS IN NEED OF PSYCHOSOCIAL TREATMENT. EFFICIENT IDENTIFICATION (ID) OF ILLIC, THOUGH, IS MORE CHALLENGING. DATA NECESSARY TO DETERMINE LIKELIHOOD OF CURABILITY ARE RECORDED IN UNSTRUCTURED EHR FIELDS, NECESSITATING LABOR-INTENSIVE, MANUAL CHART REVIEW TO IDENTIFY ILLIC. TO REALIZE THE GOAL OF PROACTIVE ID AND DELIVERY OF SCALABLE DEPRESSION CARE FOR ILLIC, ACCURATE, EFFICIENT, AUTOMATED ID APPROACHES ARE NEEDED. SELF- GUIDED DIGITAL MENTAL HEALTH INTERVENTIONS (DMHIS) CAN BE PAIRED WITH PROACTIVE ID TO DELIVER SCALABLE DEPRESSION TREATMENT. OUR TEAM PREVIOUSLY ADAPTED ONE EVIDENCE-BASED DEPRESSION TREATMENT, BEHAVIORAL ACTIVATION, FOR DELIVERY VIA A DMHI CALLED "MOODIVATE" AND DEMONSTRATED THAT MOODIVATE IS A FEASIBLE, ACCEPTABLE, AND EFFICACIOUS DMHI. THUS, A PROACTIVE TREATMENT DELIVERY MODEL USING A SELF-GUIDED DMHI SUCH AS MOODIVATE MAY BE A PROMISING APPROACH TO DELIVER EVIDENCE-BASED DEPRESSION TREATMENT TO ILLIC. [[WE HAVE CONFIRMED FEASIBILITY AND ACCEPTABILITY OF THIS APPROACH VIA A RECENT PILOT TRIAL IN WHICH WE SPECIFICALLY TAILORED MOODIVATE TO THE UNIQUE NEEDS OF ILLIC AND TESTED ALL METHODS PROPOSED HEREIN.]] IMPORTANTLY, A SUSTAINABLE MODEL MUST ADDRESS THE CHRONIC EVIDENCE-TO-PRACTICE GAP THAT LIMITS PSYCHOSOCIAL CARE DELIVERY. THUS, IMPLEMENTATION OUTCOMES AND DETERMINANTS MUST BE CONCURRENTLY EVALUATED. DIRECTLY ALIGNED WITH RFA-CA-22-027, WE PROPOSE A HYBRID TYPE I EFFECTIVENESS-IMPLEMENTATION TRIAL TO: 1) COMPREHENSIVELY ASSESS THE EFFECTIVENESS OF A PROACTIVE ID + DMHI APPROACH AMONG ILLIC, 2) GATHER INFORMATION ON INTERVENTION DELIVERY TO GUIDE IMPLEMENTATION BEST PRACTICES, AND 3) DEVELOP AN EHR-DERIVED PHENOTYPE OF LIKELY INCURABLE CANCER. OUR DIVERSE STAKEHOLDER ADVISORY BOARD, WHICH INCLUDES ILLIC, ONCOLOGY PROVIDERS, AND ORGANIZATIONAL LEADERS, HAS GUIDED AND REFINED THIS PROPOSAL TO ENSURE ITS CLINICAL RELEVANCE AND WILL CONTINUE TO PARTNER WITH OUR TEAM ON ALL ASPECTS OF THE STUDY DESIGN, IMPLEMENTATION, AND DISSEMINATION OF STUDY FINDINGS. THIS PROGRAM OF RESEARCH HAS THE POTENTIAL TO EXPAND EVIDENCE-BASED PSYCHOSOCIAL TREATMENT ACCESS IN A MANNER THAT IS SCALABLE ACROSS ONCOLOGY SETTINGS AND ULTIMATELY DECREASE THE UNDUE BURDEN OF DEPRESSION SHOULDERED BY ILLIC.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $98.5k | 8/7/25 | ||
| Not listed | $613.3k | 7/28/25 | ||
| Not listed | $621.7k | 7/16/24 |